ERBB2 and colorectal carcinoma: The intracellular portion typically includes essential signaling domains such as CD3, CD28, and CD8α.385 Current targets under investigation in clinical trials registered on ClinicalTrials.gov include HER2, epithelial cell adhesion molecule (EpCAM), and mesothelin, alongside antigens such as NK group 2 member D ligand (NKG2DL), MUC-1, and CD133, which are significantly overexpressed in CRC.386